T. Khanh

4.4k citations

57 papers · 2.5k indexed · h-index 26

Impact in

Oncology top 2%
- PARP inhibition in cancer therapy
- Cancer-related Molecular Pathways
Cancer Research top 5%
- Carcinogens and Genotoxicity Assessment

Papers in

Oncology 33
- PARP inhibition in cancer therapy 11
- Cancer-related Molecular Pathways 7
Cancer Research 11
- Cancer Genomics and Diagnostics 8

Co-authors: Shivaani Kummar James H. Doroshow Sally A. Amundson Albert J. Fornace Alice P. Chen Paul S. Meltzer Michael Bittner Jeffrey M. Trent
Journals: Cancer Research (9 papers)Clinical Cancer Research (8 papers)Journal of Clinical Oncology (5 papers)Investigational New Drugs (4 papers)Annals of Oncology (4 papers)
Partner nations: United States United Kingdom Spain

In The Last Decade

T. Khanh

54 papers receiving 2.5k citations

Peers

Countries citing papers authored by T. Khanh

Since Specialization

Citations

This map shows the geographic impact of T. Khanh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T. Khanh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T. Khanh more than expected).

Fields of papers citing papers by T. Khanh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by T. Khanh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T. Khanh. The network helps show where T. Khanh may publish in the future.

Co-authors

The 25 scholars most cited alongside T. Khanh, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with T. Khanh Line = papers co-authored together T. Khanh links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Safety and Tolerability of Berzosertib, an Ataxia-Telangiectasia–Related Inhibitor, and Veliparib, an Oral Poly (ADP-ribose) Polymerase Inhibitor, in Combination With Cisplatin in Patients With Refractory Solid Tumors JCO Precision Oncology ·Geraldine O’Sullivan Coyne, T. Khanh, Shivaani Kummar, Sarina A. Piha‐Paul, Larry Rubinstein, Robert J. Kinders, Ralph E. Parchment, Deborah Wilsker, Katherine V. Ferry‐Galow, Brandon Miller, Naoko Takebe, Lamin Juwara, Юнади Саит-Хамсанович Есиев, Ashley Bruns, Lin Huag, Abdul Rafeh Naqash, Arjun Mittra, Andrea Regier Voth, James H. Doroshow, Doctor Mukhawana	2025	0
2	First-in-human phase I/II, open-label study of mRNA-2416 alone or combined with durvalumab in patients with advanced solid tumors and ovarian cancer The Oncologist ·Ryan J. Sullivan, Oladapo Yeku, Deanna Teoh, Shilpa Gupta, Daniela Matei, Andressa S. Laino, Jing Sun, Li Zhu, Pedro Semprebom, Stéphanie Pascarella, Sima J. Zacharek, T. Khanh, Antonio Jimeno	2025	2
3	A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors Clinical Cancer Research ·Gregory M. Coté, Bose Kochupurakkal, T. Khanh, Andrea J. Bullock, Michael L. Cheng, Alona Muzikansky, Daniel E. McLoughlin, James M. Cleary, Tamara Hubetska, Aparna R. Parikh, Jong Chul Park, Colin D. Weekes, Oladapo Yeku, Lee Zou, Geoffrey I. Shapiro	2024	4
4	Navigating Informed Consent: Practices and Perceptions in Clinical Trials in Ho Chi Minh City, Vietnam Thi Thu Le, D. Nicholl, T. Khanh, Patrick M. Burritt, I.V. Zhyganyuk	2023	0
5	664P Final results of a phase I/II study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors Annals of Oncology ·Ryan B. Corcoran, T. Khanh, James M. Cleary, Aparna R. Parikh, Oladapo Yeku, Colin D. Weekes, Leanne G. Ahronian, Gianluca Mauri, Ju Tian, Joan S. Brugge, Dejan Juric, K. T. Flaherty, Ryan J. Sullivan, Jeffrey W. Clark, Rebecca S. Heist, U. Matulonis, J.F. Liu, Geoffrey I. Shapiro	2023	1
6	Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors Clinical Cancer Research ·T. Khanh, Bose Kochupurakkal, Gaurav Bhawnani, Zhongguang Wu, Veronica Lynn Li, Zeno Reinhardt, Lukas Daßler, J. De Weerdt, Nelson Gould, Kalindi Parmar, Jean‐Bernard Lazaro, Alan D. D’Andrea, Geoffrey I. Shapiro	2021	71
7	Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations Clinical Cancer Research ·Elio Adib, Katarzyna Klonowska, Krinio Giannikou, T. Khanh, Adinda Satria, 正峰尾崎, Dmitry Nikolaevich Rubtsov, Veronica Lynn Li, Anna Berto, Lynette M. Sholl, Junko Tsuji, David M. Hyman, Filadelfo Insolera, Geoffrey I. Shapiro, Hebert Alberto Vargas, James J. Harding, Martin H. Voss, Gopa Iyer, David J. Kwiatkowski	2021	37
8	Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations) JCO Precision Oncology ·Haider Mahdi, Navid Hafez, Deborah B. Doroshow, Davendra Sohal, Dhea Nurisma, T. Khanh, Patricia LoRusso, Juliane M. Jürgensmeier, T. Faus‐Keßler, Jeffrey Sklar, Colin P. Glover, Brunella Felicetti, Emma Dean, Peter G. Mortimer, Geoffrey I. Shapiro, Joseph P. Eder	2021	56
9	Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors Investigational New Drugs ·Shivaani Kummar, Apurva K. Srivastava, Tony Navas, Franco Cecchi, Young Ho Lee, Donald P. Bottaro, Sook Ryun Park, T. Khanh, Woondong Jeong, Barry C. Johnson, Andrea Regier Voth, Larry Rubinstein, James R. Wright, Ralph E. Parchment, James H. Doroshow, Alice P. Chen	2021	6
10	A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid Tumors Clinical Cancer Research ·Sara M. Tolaney, T. Khanh, Joseph P. Eder, Patricia LoRusso, Colin D. Weekes, Sarat Chandarlapaty, Ching‐Wei Chang, S. S. Bkhattacharya, 達也辻井, Eduardo Augusto Costa, Flávia Brunstein, Montserrat Carrasco‐Triguero, Walter C. Darbonne, Jennifer M. Giltnane, W. Michael Flanagan, S. Renee Commerford, Alexander Ungewickell, Geoffrey I. Shapiro, Shanu Modi	2020	15
11	A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma British Journal of Cancer ·Geoffrey I. Shapiro, Patricia LoRusso, Afshin Dowlati, T. Khanh, Caron A. Jacobson, Ulka N. Vaishampayan, Amy Weise, Paolo F. Caimi, Joseph P. Eder, Christopher A. French, Emily Labriola–Tompkins, Frédéric Boisserie, William E. Pierceall, Jianguo Zhi, Sharon Passe, Mark DeMario, Martin Kornacker, Philippe Armand	2020	83
12	First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1 Clinical Cancer Research ·Neeta Somaiah, Matthew S. Block, Joseph W. Kim, Geoffrey I. Shapiro, T. Khanh, Patrick Hwu, Joseph P. Eder, Robin L. Jones, Hailing Lu, Jan H. ter Meulen, Chet Bohac, Michael Chen, Frank J. Hsu, Sacha Gnjatic, Seth M. Pollack	2019	71
13	The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition Clinical Cancer Research ·Kalindi Parmar, Bose Kochupurakkal, Jean‐Bernard Lazaro, Zhigang C. Wang, Sangeetha Palakurthi, Paul T. Kirschmeier, Chunyu Yang, Larissa A. Sambel, Anniina Färkkilä, Elizaveta Reznichenko, Hunter D. Reavis, Connor E. Dunn, Lee Zou, T. Khanh, Panagiotis A. Konstantinopoulos, Ursula A. Matulonis, Joyce F. Liu, Alan D. D’Andrea, Geoffrey I. Shapiro	2019	103
14	Synergy of WEE1 and mTOR Inhibition in Mutant KRAS -Driven Lung Cancers Clinical Cancer Research ·Josephine Hai, Shengwu Liu, Lauren E. Bufe, T. Khanh, Ting Chen, Xiaoen Wang, Christine Ng, Shuai Li, Ming‐Sound Tsao, Geoffrey I. Shapiro, Kwok‐Kin Wong	2017	28
15	Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis) Journal of Clinical Oncology ·Shivaani Kummar, Geraldine O’Sullivan Coyne, T. Khanh, Barış Türkbey, Paul S. Meltzer, Eric C. Polley, Peter L. Choyke, Robert Meehan, Rasa Vilimas, Yvonne Horneffer, Lamin Juwara, Ha-Mong Sim, Lucía Celia, Sandra A. Mitchell, Lee J. Helman, James H. Doroshow, Alice P. Chen	2017	136
16	A phase 1 study of SY-1365, a selective CDK7 inhibitor, in adult patients with advanced solid tumors Annals of Oncology ·Anthony W. Tolcher, T. Khanh, Emmanuelle di Tomaso, Nigel J. Waters, Edgar Paúl Suntasig Masabanda, David A. Roth, Geoffrey I. Shapiro	2017	2
17	Establishing proof of mechanism: Assessing target modulation in early-phase clinical trials Seminars in Oncology ·Shivaani Kummar, T. Khanh, Geraldine O’Sullivan Coyne, Alice P. Chen, Jiuping Ji, Larry Rubinstein, James H. Doroshow	2016	6
18	Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors Journal of Clinical Oncology ·T. Khanh, Deborah Wilsker, Jiuping Ji, Jennifer Zlott, Tomoko Freshwater, Robert J. Kinders, Jerry M. Collins, Alice P. Chen, James H. Doroshow, Shivaani Kummar	2015	255
19	Antiangiogenic approaches for the treatment of advanced synovial sarcomas Current Opinion in Oncology ·T. Khanh, James H. Doroshow, Shivaani Kummar	2012	2
20	Integrating Global Gene Expression and Radiation Survival Parameters across the 60 Cell Lines of the National Cancer Institute Anticancer Drug Screen Cancer Research ·Sally A. Amundson, T. Khanh, Lisa C. Vinikoor, 衣川恵, Christine A. Koch-Paiz, Jae-Yong Ahn, Mark Reimers, Yidong Chen, Dominic A. Scudiero, John N. Weinstein, Jeffrey M. Trent, Michael Bittner, Paul S. Meltzer, Albert J. Fornace	2008	207

About T. Khanh

T. Khanh is a scholar working on Oncology, Cancer Research, Biotechnology, Molecular Biology and Pulmonary and Respiratory Medicine, having authored 57 papers that have together received 2.5k indexed citations. Recurring topics across this work include DNA Repair Mechanisms (13 papers), PARP inhibition in cancer therapy (11 papers), Cancer Genomics and Diagnostics (8 papers), Cancer-related Molecular Pathways (7 papers), PI3K/AKT/mTOR signaling in cancer (5 papers), Advanced Breast Cancer Therapies (5 papers), Cancer Research and Treatments (5 papers) and Effects of Radiation Exposure (4 papers). The work is most often cited by research in Oncology (991 citations), Cancer Research (473 citations), Molecular Biology (1.6k citations), Radiology, Nuclear Medicine and Imaging (422 citations) and Pulmonary and Respiratory Medicine (462 citations). T. Khanh has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include Shivaani Kummar, James H. Doroshow, Sally A. Amundson, Albert J. Fornace, Alice P. Chen, Paul S. Meltzer, Michael Bittner, Jeffrey M. Trent, Geoffrey I. Shapiro and Robert J. Kinders. Their work appears in journals such as Cancer Research, Clinical Cancer Research, Journal of Clinical Oncology, Investigational New Drugs and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact